<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We recently demonstrated that p38α is required to maintain <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) metabolism, as its inhibition leads to FoxO3A activation, autophagy, cell <z:hpo ids='HP_0011420'>death</z:hpo>, and <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> reduction both in vitro and in vivo </plain></SENT>
<SENT sid="1" pm="."><plain>Here we show that inhibition of p38α is followed by TRAIL-mediated activation of caspase-8 and FoxO3A-dependent HER3 upregulation with consequent overactivation of the MEK-ERK1/2 survival pathway </plain></SENT>
<SENT sid="2" pm="."><plain>p38α and MEK combined inhibition specifically induces <z:mpath ids='MPATH_3'>apoptosis</z:mpath> by enabling TRAIL signaling propagation through t-Bid and caspase-3, and fosters cell <z:hpo ids='HP_0011420'>death</z:hpo> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells and preclinical mouse models </plain></SENT>
<SENT sid="3" pm="."><plain>Current MEK1-directed pharmacological strategies could thus be exploited, in combination with p38α inhibition, to develop new approaches for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> treatment </plain></SENT>
</text></document>